Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $27.73, marking a -5.13% move from the previous day.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.18, denoting a +1.64% move from the preceding trading day.
Viking Therapeutics: Market Betting On Big Upside Through 2030
Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging global expansion and late-stage development to compete with incumbents Lilly and Novo Nordisk. Nothing is over just yet. Phase 3 for VK2735 Oral is set for late 2026, with initial commercial ramp expected in 2028 and potential $1.3B sales by 2030. A hockey stick inflection could pan out.
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge
Buy the story, sell the news. That's a reasonable explanation for why Viking Therapeutics NASDAQ: VKTX fell over 3% the day the company delivered its Q1 2026 earnings report.
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) closed at $32.8 in the latest trading session, marking a -4.23% move from the prior day.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) reached $35.52 at the closing of the latest trading day, reflecting a +1.46% change compared to its last close.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
